Mechanisms of Antigen Escape from BCMA- or GPRC5D-Targeted Immunotherapies in Multiple Myeloma

To examine the tumor-intrinsic factors that promoted multiple myleoma antigen escape, researchers performed combined bulk and single-cell whole-genome sequencing and copy number variation analysis of 30 patients treated with anti-B cell maturation antigen (BCMA) and/or anti-GPRC5D CAR T/bispecific T cell engager therapy.